Stay updated with breaking news from Zenith Epigenetics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ipatasertib plus trastuzumab and pertuzumab as frontline maintenance therapy was effective and safe in PIK3CA-mutant, HER2-positive advanced breast cancer.
The growth of the metastatic castrate-resistant prostate cancer market is expected to be driven by the expected rising prevalence of prostate cancer cases due...
/PRNewswire/ -- DelveInsight's Metastatic Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices,...
/PRNewswire/ -- DelveInsight's Metastatic Castration-Sensitive Prostate Cancer Market Insights report includes a comprehensive understanding of current...
DelveInsight’s, “Prostate Cancer Pipeline Insight 2023” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in the Prostate Cancer pipeline landscape. It covers the